Roche Holding | ROG - Pre Tax Profit


Roche Holding reported CHF4.79B in Pre-Tax Profit for its fiscal semester ending in June of 2025.





Pre Tax Profit Change Date
AbbVie USD 5.57B 2.9B Mar/2026
Alcon AG USD 264M 19M Dec/2025
Almirall EUR 30.32M 22M Dec/2025
Amgen USD 1.51B 2.41B Dec/2025
AstraZeneca USD 3.91B 1.28B Mar/2026
Bayer EUR -1.16B 735M Sep/2025
Biogen USD 377.7M 433.7M Mar/2026
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Fresenius EUR 601M 122M Dec/2025
Fresenius Medical Care EUR 508.46M 105.89M Dec/2025
Galapagos EUR -221.49M 117.07M Sep/2025
Genmab DKK 55M 427M Dec/2025
Gilead Sciences USD 2.08B 1.56B Dec/2025
GlaxoSmithKline GBP 2.14B 919M Mar/2026
GRIFOLS EUR 190.51M 20.03M Jun/2025
Hikma Pharmaceutical USD 147.5M 3.5M Jun/2025
Lonza CHF 624M 197M Dec/2024
Merck EUR 1.29B 458.1M Sep/2025
Merck USD 3.42B 3.32B Dec/2025
Novartis USD 4.64B 445M Dec/2025
Orion EUR 113.4M 213.6M Mar/2026
Pfizer USD 3.33B 290M Sep/2025
Philips EUR 275M 62M Sep/2025
Recordati EUR 144.95M 25.46M Sep/2025
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sanofi EUR -1.16B 5.5B Dec/2025
UCB EUR 789M 427M Jun/2025